<DOC>
	<DOC>NCT00373906</DOC>
	<brief_summary>Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.</brief_summary>
	<brief_title>Velcade in MALT Lymphoma Patients</brief_title>
	<detailed_description>The objectives of this study are to evaluate the effectivity and the safety of bortezomib in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation. It is a phase II prospective single arm study with a target sample of 16 patients. 1.5mg/m2 Bortezomib is given intravenously on day 1,4,8,11 every three week, for a maximum of 8cycles.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>patients with histologically confirmed MALT lymphoma with measurable disease (stage IIV) with first or greater relapse after HPeradication, radiation or chemotherapy , age &gt; 18 years must be able to tolerate therapy and have adequate cardiac, renal and hepatic function ECOG status of &lt;_ 2 must be capable of understanding the purpose of the study and given written informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>MALT Lymphoma, Bortezomib</keyword>
</DOC>